These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20809685)

  • 1. To flow or not to flow - a matter of life and death.
    Beyar R
    Acute Card Care; 2010 Sep; 12(3):79-80. PubMed ID: 20809685
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of the no-reflow phenomenon.
    Butler MJ; Chan W; Taylor AJ; Dart AM; Duffy SJ
    Pharmacol Ther; 2011 Oct; 132(1):72-85. PubMed ID: 21664376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No-reflow: the next challenge in treatment of ST-elevation acute myocardial infarction.
    Abbate A; Kontos MC; Biondi-Zoccai GG
    Eur Heart J; 2008 Aug; 29(15):1795-7. PubMed ID: 18617478
    [No Abstract]   [Full Text] [Related]  

  • 4. New strategies for the management of no-reflow after primary percutaneous coronary intervention.
    Niccoli G; Cosentino N; Spaziani C; Minelli S; Fracassi F; Crea F
    Expert Rev Cardiovasc Ther; 2011 May; 9(5):615-30. PubMed ID: 21615325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No-reflow: Still searching for that magic bullet.
    Gilchrist IC
    Catheter Cardiovasc Interv; 2010 Nov; 76(6):794. PubMed ID: 21104769
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of metabolic syndrome on no-reflow after primary percutaneous coronary intervention in patients with acute ST elevation myocardial infarction.
    Celik T; Iyisoy A
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):e21-2. PubMed ID: 18378434
    [No Abstract]   [Full Text] [Related]  

  • 7. The no-reflow phenomenon.
    Galiuto L; Rebuzzi AG; Crea F
    JACC Cardiovasc Imaging; 2009 Jan; 2(1):85-6. PubMed ID: 19356539
    [No Abstract]   [Full Text] [Related]  

  • 8. Myocardial no-reflow treatment.
    Muller O; Trana C; Eeckhout E
    Curr Vasc Pharmacol; 2013 Mar; 11(2):278-85. PubMed ID: 23506504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The challenges and impact of microvascular injury in ST-elevation myocardial infarction.
    Reinstadler SJ; Stiermaier T; Fuernau G; de Waha S; Desch S; Metzler B; Thiele H; Eitel I
    Expert Rev Cardiovasc Ther; 2016; 14(4):431-43. PubMed ID: 26794717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol.
    Niccoli G; D'amario D; Spaziani C; Cosentino N; Marino M; Rigattieri S; Schiavo PL; De Vita MR; Tarantino F; Bartorelli A; Fabbiocchi F; Prati F; Imola F; Valgimigli M; Ferrari R; Crea F
    J Cardiovasc Med (Hagerstown); 2009 Jul; 10(7):585-92. PubMed ID: 19384242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of microvascular injury after acute myocardial infarction: importance of the area at risk.
    Klem I; Kim RJ
    Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):756-7. PubMed ID: 18852712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome is a predictor for an ECG sign of no-reflow after primary PCI in patients with acute ST-elevation myocardial infarction.
    Tartan Z; Ozer N; Uyarel H; Akgul O; Gul M; Cetin M; Kasikcioglu H; Cam N
    Nutr Metab Cardiovasc Dis; 2008 Jul; 18(6):441-7. PubMed ID: 17981019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of admission glomerular filtration rate on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction.
    Celik T; Iyisoy A; Yuksel CU; Kilic S; Yilmaz MI; Akgul EO; Jata B; Isik E
    Coron Artery Dis; 2008 Dec; 19(8):543-9. PubMed ID: 19005288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory.
    Rezkalla SH; Kloner RA
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):950-7. PubMed ID: 19021281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous coronary intervention and the no-reflow phenomenon.
    van Gaal WJ; Banning AP
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):715-31. PubMed ID: 17605650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit.
    Hale SL; Kloner RA
    J Cardiovasc Pharmacol Ther; 2008 Sep; 13(3):226-32. PubMed ID: 18625805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization.
    Niccoli G; Lanza GA; Shaw S; Romagnoli E; Gioia D; Burzotta F; Trani C; Mazzari MA; Mongiardo R; De Vita M; Rebuzzi AG; Lüscher TF; Crea F
    Eur Heart J; 2006 Aug; 27(15):1793-8. PubMed ID: 16829540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The no-reflow phenomenon following percutaneous coronary intervention].
    Schwartzenberg S; Halkin A; Finkelstein A; Keren G; Banai S
    Harefuah; 2009 Jun; 148(6):381-5, 411. PubMed ID: 19902604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Culprit or multivessel treatment for STEMI: the opinion of a repented principal investigator.
    Di Mario C
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):171-3. PubMed ID: 21290552
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention.
    Niccoli G; Giubilato S; Russo E; Spaziani C; Leo A; Porto I; Leone AM; Burzotta F; Riondino S; Pulcinelli F; Biasucci LM; Crea F
    Eur Heart J; 2008 Aug; 29(15):1843-50. PubMed ID: 18617477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.